Related Experiment Video
Updated: Jul 13, 2025
Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development
Published on: September 4, 2021
An effective treatment in Erdheim Chester disease: vemurafenib: a case report
Ersin Bozan1, Tahir Darçın2, Samet Yaman2
1Department of Hematology and Bone Marrow Transplantation Center, Hematology and Bone Marrow Transplantation Unit, Health Sciences University Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey. ersinbozan87@gmail.com.
Background:
Erdheim Chester disease (ECD) is a rare disease with multisystemic involvement in the group of non-langerhans cell histiocytosis. Although nearly 100 years have passed since its definition, the number of cases reported all over the world is below 1000. In addition to the rarity of the disease, low awareness seems to play a role in this.
Case Presentation:
47-year-old white caucasian women patient who presented to our clinic with symptoms of weakness-fatigue as well as increasing pain in the knees and ptosis in the left eye. Result of the patient's bone biopsy, ECD was considered pathologically and BRAF V600E mutation was shown molecularly. After presenting the clinical, laboratory and other examination results of the case, the dramatic response seen with targeted therapy will be discussed.
Conclusions:
BRAF V600E mutation is frequently seen in ECD. Vemurafenib plays an active role in targeted therapy.
More Related Videos
06:25Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
Published on: March 29, 2024
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
Related Concept Videos
02:56Treatment Resistant Cancers
02:38Mitogens and the Cell Cycle